Vivos Inc (OTCMKTS: RDGL) continues to move steadily northbound taking out the highs of early February and moving back over $0.07 with steady buying and little selling. RDGL is a biotech sleeper who continues to see great success with RadioGel™ a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. Currently approved for animal use as IsoPet® it has proven to be effective in killing cancer tissue near the injections in animals. It is most effective in early cases before the cancer has begun to spread. Later stage cancers are more difficult to treat since the tendrils from the primary cancer site are not well defined and therefore can lead to recurrence. 

The Company’s plan is to incorporate the data assembled from its work with Isopet® in animal therapy to support the Company’s efforts in the development of RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. Vivos is now entering the final phase of validating its essential procedures. This process includes production to specification, sterility, shelf-life, and pre-mixing of components, all necessary data to address critical sections of the upcoming IDE submittal. We will be updating on RDGL when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below. 

Vivos Inc (OTCMKTS: RDGL) is a radiation oncology medical device company engaged in the development of its yttrium-90 Y-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer. 

The Company has developed Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers. 

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected. RadioGel can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members. 

The IsoPet® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet® to University animal hospitals and private veterinary clinics. 

Over the years, Vivos has established a valuable intellectual property portfolio and recently expanded its intellectual property protection on several fronts. The Company’s patent team has already filed its particle patent in more than ten patent offices that collectively cover 63 countries throughout the world. Vivos also filed a provisional patent number 63-299,930 giving it broader protection on recent and projected developments on both our hydrogel and our particle components. In January the Company filed a utility patent application on a range of particles for precision radionuclide therapy as a follow-up to its provisional patent filed on 1/15/2022. This patent was filed in the USA and internationally via the Patent Cooperation Treaty, PCT. This includes Canada, the European Union, Japan, Australia, Brazil, China, India, South Korea, and the Russian Eurasian (Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, and Turkmenistan). 

Vivos currently has four regional therapy clinics: 

• Vista Veterinary Hospital – Kennewick, WA
• University of Missouri – Columbia, MO
• Johns Hopkins University – Baltimore, MD
• New England Equine Practice – Patterson, NY

I remember them saying 17 or 18 different types of cancers can be treated with RadioGel someday. Many indications. Imagine the revenues generated,,,Imagine the number of lives saved! $RDGL https://t.co/VIKN0d49g4

— smiles (@doccjc62) March 1, 2023

To Find out the inside Scoop on RDGL Subscribe to newsytrends.com Right Now by entering your Email in the box below

Vista Veterinary Hospital was selected as the pilot private clinic to initiate commercial sales of IsoPet®. It is good management practice to implement and learn from a pilot program before spreading to regional clinics across the country. Vista is located in the Tri-Cities Washington area which is convenient for interactions with key personnel of the Company. The pilot is being used to 

The testing at the universities and at Vista Veterinary Hospital have demonstrated once again that IsoPet® is effective on killing cancer tissue near the injections. It is most effective in early cases before the cancer has begun to spread. Later stage cancers are more difficult to treat since the tendrils from the primary cancer site are not well defined and therefore can lead to recurrence. 

Vista Veterinary Hospital accepted advanced cancer cases and has gained experience to extend the animal’s lives. In one case, a cat was terminally ill and had previously had external beam, surgery and chemotherapy. The facial tumor was treated with 400 Gy and the biopsy confirmed that the cancer was killed. In about seven months the cancer returned in the throat and could not be treated so the cat had to be put down. Dr. Bauder, the veterinarian pet parent, was still elated about the life extension and is asking Vivos to use him as a reference. Another animal, Yukon had a large tumor on his leg that was recommended for amputation. The tumor size decreased 50% after the first treatment, but then stopped decreasing. For the first time a second therapy was administered and the tumor has continued to decrease in size. Yukon’s life was extended for more than a year until she finally succumbed to metastatic cancer in another location. 

Since IsoPet® has shown to be effective in killing cancer at the site of injection the current focus is in optimizing the techniques to help the pet resorb the necrotic tissue rapidly. In addition, IsoPet® was used to treat a mast cell tumor. When these cancers are destroyed, they release their mast cell. The animal was treated with a steroid to counter this effect and to date is doing well. 

The Company’s efforts are now to obtain more early-stage cancer patients and they have worked closely with FX Masse to develop nine certification training modules for use in potential regional clinics. These modules are necessary to satisfy the radioactive material handling licenses. This approach is very cost effective. 

Johns Hopkins University VCTN, Veterinary Clinical Trials Network, is now an Isopet® regional clinic. Additionally, Johns Hopkins will also perform new Isopet® animal studies on various specific cancers. They have the required radioactive material license and have completed their training certification for Isopet®. This important relationship will also help meet the Company’s objective of obtaining high quality data on a range of cancers that can be published in leading journals. These publications are the optimal way to increase awareness of Isopet® and to gain broader acceptance from the veterinarian/oncology community. 

The Company’s objective is to open several regional clinics by the end of 2023 and to participate in a minimum of four conferences to spread the word about IsoPet in the veterinarian community for treating tumors in small animals and horses. Vivos created a Marketing Steering Board to provide advice on obtaining new pet patients. 

This exact same advantage and numerous others will be delivered with RadioGel to #human #cancer patients.

IsoPet is our brand name for RadioGel, and is currently being successfully administered at licensed Regional Clinics in the #USA.#CancerTreatment #CancerAwareness $RDGL https://t.co/HCtDms3wEW

— RadioGel™ (@radiogel) March 5, 2023

 We have something big coming Subscribe Right Now!

Currently trading at a $26 million market valuation RDGL os is 361,379,028 with around 335,314,232 shares in the public float. A fully reporting SEC filer biotech with $1 million in cash in the treasury and debt free, RDGL is head and shoulders above most that trade on this exchange. As we said; RDGL is a biotech sleeper who continues to see great success with RadioGel™ a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. Currently approved for animal use as IsoPet® it has proven to be effective in killing cancer tissue near the injections in animals. The Company’s plan is to incorporate the data assembled from its work with Isopet® in animal therapy to support the Company’s efforts in the development of RadioGel™ device candidate, including obtaining approval from the FDA to market and sell RadioGel™ as a Class II medical device. Vivos is now entering the final phase of validating its essential procedures. This process includes production to specification, sterility, shelf-life, and pre-mixing of components, all necessary data to address critical sections of the upcoming IDE submittal. RDGL has plenty of liquidity, a long history of big moves running to over $0.30 both in 2018 and in 2021 and has a significant shareholder base with at least 1,200 shareholders of record and growing. We will be updating on RDGL when more details emerge so make sure you are subscribed to Newsytrends.com by entering your email below. 

Disclosure: we hold no position in RDGL either long or short and we have not been compensated for this article.